NCT07405086 2026-02-12
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
OHSU Knight Cancer Institute
Qingdao Sino-Cell Biomedicine Co., Ltd.
UNICANCER
Eastern Cooperative Oncology Group
Rapa Therapeutics LLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The Christie NHS Foundation Trust
Hunan Cancer Hospital
The First People's Hospital of Changzhou